Straight from the Podium
Top Slides from #ESMOGI26
The most-viewed conference slides shared by GI KOLs — data tables, forest plots, and study designs, live from Munich. Click any card to open the original post.
Who's Driving the Conversation
Top KOL Voices
Ranked by total impressions across ESMO GI 2026 tweets. Physician voices only (registry-verified).
Tweets & Trials
Trial Buzz by GI Subtype
Expand any trial to see the verbatim KOL tweets driving it. Ordered by conversation volume.
Pancreatic (incl. PDAC)31 tweets · 5 trials
RMC-GI-102zoldonrasib + chemo · 1L RAS G12D mPDAC
▼
Safety and efficacy of zoldonrasib plus chemotherapy in 1L RAS G12D metastatic PDAC
@ ESMO-GI
👏amazing response rates
👉favorable toxicity, combos feasible
🧐A new era in PDAC therapy
@myESMO @ASCO
👁 2.5K❤ 26🔁 17
🚀Zoldonrasib plus chemo in 1L of PDAC with KRASG12D
proffered paper #ESMOGI26
✅Tolerable
✅ORR 60-80%
#cancer #oncology #MedX #pancreatic
@OncoAlert
👁 1.1K❤ 22🔁 7
Non-randomised #Zoldonrasib + FOLFIRINOX/GemNab in 1L mKRAS G12D aPDAC data at @myESMO #ESMOGI26 by #BrianWolpin
Poor(er) px charact in mFOLFIRINOX
Less rash; good tolerance – good dose intensity
🥳ORR 82% mFOLFIINOX; 61% GN
😊Ph III RASolute 305 coming
#ESMOAmbassadors
👁 1.0K❤ 22🔁 12
🧬 KRAS G12D is no longer an “undruggable” target. #ESMOGI26
🚀 Zoldonrasib + ChT showed promising early activity in 1L PDAC:
📈 ORR 82% + mFOLFIRINOX (DCR 96%)
📈 ORR 61% + Gem/Nab-P (DCR 90%)
✅ No new safety signals.
⏳ Phase III RASolute 305 is now underway.
@OncoAlert
👁 888❤ 23🔁 13
Zoldonrasib + chemotherapy in first-line KRAS G12D metastatic pancreatic cancer: encouraging early signals from ESMO GI 2026.
🔹 ORR: 82% (mFOLFIRINOX) | 61% (Gem/nab-paclitaxel)
🔹 DCR: 96% | 90%
🔹 ≥50% KRAS G12D ctDNA reduction: 100% (both arms)
🔹 No new or additive safety
👁 803❤ 1🔁 1
🔥Zoldonrasib+mFFX or GnP #PDAC
➡️early efficacy data first-line
ORR 61-82% DCR 90-96%
✅safety - few added side effects
✅ctDNA molecular responses
➡️RASolute305 trial in first line
Where will it all fit in! Best combos? Best sequences ? Need chemo?
@myESMO @OncoAlert
👁 727❤ 14🔁 13
🧬 Zoldonrasib + chemotherapy shows impressive early activity in 1L KRAS G12D-mutant PDAC.
🔹 mFOLFIRINOX: ORR 82%, DCR 96%
🔹 Gem/Nab-P: ORR 61%, DCR 90%
🔹 100% of evaluable patients achieved >50% ctDNA reduction.
#ESMOGI2026 @OncoAlert
👁 409❤ 4🔁 4
Pancreatic Cancer (PDAC):
🍋KRAS G12D inhibitors (e.g., zoldonrasib + chemo: encouraging Phase 1/2 ORR 61–82%
🍋 Daraxonrasib (RMC-6236): Oral RAS(ON) multi-selective (pan-RAS-like) inhibitor
RASolute 302 (in 2L) and 303 (in Adjuvant with GemAbraxane, Phase3)
👁 99❤ 0🔁 0
RMC-9805-001zoldonrasib + daraxonrasib · 2L+ KRAS G12D mPDAC
▼
From @RevMedicines data on Zoldonrasib plus Daraxonrasib in 2nd & 3rd line metastatic #PancreaticCancer - presented at #ESMOGI26
Small numbers but even a few years back, who would have imagined survival curves like this in 2nd & 3rd line metastatic PANCREATIC cancer? Amazing!
👁 7.1K❤ 59🔁 26
🚨 RMC-9805-001 at #ESMOGI26! Can dual KRAS G12D inhibition (zoldonrasib + daraxonrasib) move the needle in KRAS G12Dm PDAC? (Phase I, 60 pretreated patients 2L/3L+)
🎯 ORR 50% in 2L and 47% in ≥3L || DCR 97% and 90%
💥 mPFS 9.6 mo in 2L, with a favorable safety profile and no
👁 2.2K❤ 12🔁 7
🧬 #ESMOGI26 Dual KRAS G12D blockade keeps gaining momentum.
🚀 Zoldonrasib + daraxonrasib showed encouraging activity in KRAS G12D PDAC:
📈 ORR 50% (2L) | 47% (3L+)
⏳ mPFS 9.6 vs 7.6 months
✅ Manageable safety profile.
Phase III RASolute 309 is next.
@OncoAlert
👁 1.6K❤ 17🔁 9
Impressive data with #Zoldonrasib + #Daraxonrasib in mKRAS G12D 2L/3L aPDAC at @myESMO #ESMOGI26
Rash 90%, 12% G3; No DLT
🤩ORR 50% 2L / 47% 3L
mPFS 9.6m 2L / 7,6m 3L
mOS NE 2L / 10.5m 3L
🎊Phase III RASolute 309 coming!
🤞🏻May we have a#ChemoFree option?
#ESMOAmbassadors
👁 1.3K❤ 25🔁 13
Safety and efficacy of zoldonrasibplus daraxonrasib in patients with 2L+ KRAS G12D metastatic mPDAC
@ ESMO-Gi
😍>90% DCR in 2nd/3rd line therapy
👉tox driven by daraxonrasib, only 5% treatment discontionuation
👉amazing..
@myESMO @ASCO
👁 980❤ 17🔁 11
🔥Improving RASinhibition with combos: KRAS G12D #PDAC
➡️Ph1 RMC-9805-001 Daraxonrasib+ zoldonrasib (pan-RASi + G12Di)
✅60 pts 2nd/ 3rd+ line
✅ORR 47-50%; DCR 90-97%
✅PFS 2nd line 9.6mths ; mOS NE
❗️Zoldonrasib very well tolerated
@myESMO @OncoAlert
👁 807❤ 17🔁 15
🚀Daraxonrasib plus Zoldonrasib in 2L and beyond of PDAC with KRASG12D
proffered paper #ESMOGI26
2L
✅ORR 50%
✅mPFS: 9.6 mo
#cancer #oncology #MedX #pancreatic
@OncoAlert
👁 758❤ 19🔁 7
Promising early signal for KRAS G12D-mutant metastatic pancreatic cancer at #ESMOGI26.
The KRAS G12D inhibitor zoldonrasib (RMC-9805) combined with chemotherapy demonstrated encouraging preliminary activity:
• mFOLFIRINOX: ORR 82%, DCR 96%
• Gemcitabine/nab-paclitaxel: ORR
👁 648❤ 11🔁 6
GLEAMzolbetuximab + GN · CLDN18.2+ mPAC
▼
#ESMOGI26
GLEAM phase II:
Zolbetuximab + GN did not improve OS or PFS in CLDN18.2+ metastatic pancreatic cancer.
OS: 13.7 vs 13.6 months
HR 1.00; p=0.499
A possible benefit signal emerged in the small IL-18-high subgroup, but this remains exploratory.
👁 8.1K❤ 20🔁 11
Zolbetuximab plus gemcitabine and nab-paclitaxel in CLDN18.2+ metastatic PDAC: phase II GLEAM study
@ESMO-GI
👉Primary endpoint not met, no OS & PFS benefit
👉Toxicity manageable
🧐Not the right drug, but maybe the right target
👁 3.3K❤ 14🔁 11
Ph2 randomised GLEAM trial #PDAC- targeting CLDN18.2
➡️no imp in OS, -ve study 13.7 v 13.6mths
➡️Zolbetuximab impacted peripheral cytokines with ⬆️in IL-18 associating with OS
➡️CLDN story not over!
���️Fab presentation with science nuggets @CentralParkWMD
@myESMO @OncoAlert
👁 670❤ 14🔁 12
📊 GLEAM | CLDN18.2+ mPDAC #ESMOGI26
First phase IIR trial of zolbetuximab in mPDAC
❌ Primary OS endpoint not met
📈 mOS: 13.7 vs 13.6 mo
🔹 ORR/DoR numerically higher
⚠️ Early discontinuation may have limited benefit
Exploratory IL-18 signal deserves further study
@OncoAlert
👁 628❤ 9🔁 7
The phase II GLEAM trial delivered a negative result in CLDN18.2-positive metastatic pancreatic cancer.
Adding zolbetuximab to gemcitabine/nab-paclitaxel did not improve overall survival:
🔹 mOS: 13.7 vs 13.6 months
🔹 HR 0.99 (P=0.50)
#ESMOGI2026 @OncoAlert
👁 449❤ 5🔁 4
GLEAM trial at @myESMO #ESMOGI26
GemNab +/- Zolbetuximab in CLDN18.2 +ve aPDAC
😔No differences in mOS or mPFS
😏ORR higher 45% vs 37.4%
If you ask me, CLDN18.2 IS a valid target in PDAC. Let’s not give up! 💪
#ESMOAmbassadors
👁 282❤ 4🔁 2
RASolute 302daraxonrasib vs chemo · 2L mPDAC · Ph3 (NEJM)
▼
🔥RAS inhibition in #PDAC #ESMOGI26
➡️Daraxonrasib as new 2nd line std
1st-line data as mono or in combo GnP
➡️G12Di in combo with chemo
➡️multiple new drugs & some falling off further dvpt
➡️optimal sequences/combos to come
⭐️all patients need access asap!
@myESMO @OncoAlert
👁 2.6K❤ 45🔁 28
Daraxonrasib in mPDAC data in 2L compared to chemotherapy results in 1L and 2L. @myESMO
👁 1.6K❤ 20🔁 12
Great discussion by Dr. Valerie Lee @Hopkins: RASolute 302 showed daraxonrasib improved OS/PFS/QoL vs chemo in previously treated RAS G12-mutant mPDAC.
Key next steps: access, AE management, and defining roles in 1L/adjuvant settings. #BestofASCO26 @TotalHealthConf
👁 1.1K❤ 13🔁 5
KRAS was "undruggable", until now.
Daraxonrasib nearly doubled survival in metastatic pancreatic cancer (13.2 vs 6.7 mo).
A standing ovation at ASCO? Absolutely deserved. The RAS revolution is officially here. 🚀 #Oncology #ASCO2026
👁 665❤ 2🔁 1
Daraxonrasib in second line showed longer survival than historical 1L and 2L regimens in mPDAC. #PancreaticCancer and sets a new benchmark . Looking foward to see more data in 1 st líne and in combination with chemo . @myESMO , @EMOGI_AAOC
👁 162❤ 3🔁 0
TRIPP-FFXP-32 microparticles + FFX · uLAPC
▼
Liver / HCC30 tweets · 3 trials
EMERALD-1durvalumab + beva + TACE · unresectable HCC (OS)
▼
Hepatocellular carcinoma is set for a huge meeting at #ESMOGI26.
Here are the Top 5 HCC abstracts I’m watching most closely 👇
1️⃣ 183O | EMERALD-1 (OS Update)
Can the overall survival benefit establish durvalumab + TACE as the new standard for embolization-eligible HCC?
2️⃣ https://t.co/g0au0Eo5dQ
👁 5.2K❤ 42🔁 19
⚡ #ESMOGI26 EMERALD-1 OS update
📈 PFS benefit confirmed with durvalumab + TACE
❌ No OS benefit in the current analysis
🧩 Early deaths, disease heterogeneity and limited post-TACE systemic therapy may have influenced outcomes.
@OncoAlert
👁 5.0K❤ 14🔁 5
EMERALD-1 Final OS Analysis
Durvalumab ± Bevacizumab + TACE in Unresectable Embolization-Eligible HCC (eeHCC)
Key findings
• Previous EMERALD-1 showed a significant PFS benefit.
• Final analysis showed no overall survival benefit with the addition of durvalumab ± bevacizumab
👁 1.3K❤ 19🔁 4
OS in EMERALD-1: A phase III study of durvalumab ± beva and TACE in unresectable embolisation-eligible HCC
👉OR & PFS improved
👉no OS benefit
🧐No safety concerns, but also not strongly supporting the combination
@myESMO @EASLedu @ILCAnews
👁 1.2K❤ 24🔁 17
#ESMOGI26
EMERALD-1 final OS:
D+B+TACE did not improve OS despite the PFS benefit.
29.9 vs 33.3 months
HR 1.10; p=0.47
Toxicity and treatment discontinuation were higher.
👁 1.1K❤ 8🔁 6
🚀EMERALD-1 OS analysis
proffered paper #ESMOGI26
❌No OS benefit
✅PFS benefit
#cancer #oncology #MedX #GI @OncoAlert
👁 963❤ 15🔁 11
EMERALD-1 final OS results presented at #ESMOGI26
While adding durvalumab + bevacizumab to TACE significantly improved PFS (HR 0.77), this benefit did not translate into an overall survival advantage (OS HR 1.10). Durvalumab alone also failed to improve OS (HR 0.93).
@OncoAlert
👁 529❤ 10🔁 5
💥 EMERALD-1 at #ESMOGI26! Can adding durvalumab ± bevacizumab to TACE improve outcomes in unresectable HCC?
▪️ TACE + D + B significantly improved PFS (HR 0.77) || D alone showed only a numerical PFS improvement
🔴 Neither strategy improved OS versus TACE alone
Long treatment
👁 444❤ 13🔁 5
EMERALD-3trem + durva ± len + TACE · eeHCC
▼
EMERALD-3 may redefine treatment for embolization-eligible HCC.
Adding STRIDE + TACE significantly improved PFS, ORR and DoR versus TACE alone, with a manageable safety profile.
Early OS trend is encouraging, although longer follow-up is awaited.
Will this change the practice?
👁 2.5K❤ 7🔁 5
Tumour response analyses by RECIST v1.1 and mRECIST in the phase III EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib TACE in HCC
@ESMO-GI
👉Primary endpoint met
👉ORR & PFS improved
👉OS benefit for STRIDE
🧐Option to be considered
@myESMO @ASCO
👁 1.7K❤ 30🔁 18
🚀EMERALD-3 response analysis
proffered paper #ESMOGI26
✅ORR and PFS benefit
#cancer #oncology #MedX #GI @OncoAlert
👁 1.3K❤ 26🔁 13
Absolutely not.
It is no surprise that EMERALD-3 and the studies shown in the attached slide will be “positive” when the comparator delivers such poor local control, with TACE failure rates of 40% to 60%.
These studies represent a misallocation of resources. We can and should
👁 606❤ 10🔁 2
🗣️ EMERALD-1 & EMERALD-3 discussion #ESMOGI26
🎯 PFS alone may not be enough.
⚖️ OS remains the key endpoint.
🧩 Patient selection, early mortality, toxicity and post-TACE treatment sequencing matter.
The role of IO + TACE continues to evolve.
@OncoAlert
👁 520❤ 8🔁 8
Data on #ORR from #EMERALD3 at @myESMO #ESMOGI26
Following the @ASCO data (see post below), response data by RECIST and mRECST presented today
#ESMOAmbassadors https://t.co/Up1nprKiWl
👁 470❤ 4🔁 3
Is CTLA-4 the key to unlocking an OS benefit in the post-TACE setting? The OS curves from EMERALD-1 and EMERALD-3 raise an intriguing question. Great discussion on IO strategies in HCC at #ESMOGI26. Looking forward to the final OS results from EMERALD-3.
👁 83❤ 1🔁 0
PROACTIFY90-SIRT · HCC real-world data
▼
PROACTIF #ESMOGI26 @myESMO
❗️✅Dosing is crucial with TARE in HCC
#cancer #oncology #MedX @OncoAlert
👁 1.6K❤ 20🔁 12
⚡ Rapid Oral Session at #ESMOGI26
🔸 PROACTIF / Y-90
🔸 AGEO-NEO-MSI
🔸 CAPRI-2 GOIM
🔸 Anti-EGFR retreatment
🧬 From real-world evidence to biomarker-driven strategies.
Promising data across GI cancers—now awaiting prospective confirmation and longer follow-up.
@OncoAlert
👁 1.5K❤ 28🔁 15
PROACTIF #HCC #iCCA #ESMOGI26
➡️largest Real World dataset Y-90
➡️989 HCC; 207 iCCA
➡️HCC 68% >5cm; 35% PVT
➡️Absorbed dose matters
➡️impressive outcomes VP1-3
❗️IO Combos to date with TACE but increasing role Y90 globally!
@myESMO @OncoAlert
👁 1.2K❤ 20🔁 13
Results from the #observational PROACTIF study on #radioembolisation in #HCC at @myESMO #ESMOGI26
👉Dose matters
📈Vp 1/2/3/4 are NOT all the same
🤞🏻1-3 may behave as non-PVT - worth considering TARE if elegible…
🤨My mental note: Vp4 need options/trials
#ESMOAmbassadors
👁 1.2K❤ 17🔁 12
Effectiveness & safety of SIRT using yttrium-90 glass microspheres for HCC
@eClinicalMed
https://t.co/1P31BU6kU0
🔎RWD multi-center prospective PROACTIF, 989 pts pts
👉mOS: 21⋅8 mo
👉ORR: 45%, 10⋅7% underwent surgery
🧐interesting & supportive, but not overly impressive OS
👁 779❤ 14🔁 7
Y-90 SIRT in large HCC: treat the dose, not just the size.
The PROACTIF registry suggests higher tumor absorbed dose was associated with substantially longer overall survival—even in selected patients with portal vein thrombosis. Real-world evidence that supports personalized
👁 753❤ 12🔁 5
🚨 PROACTIF at #ESMOGI26! Y-90 radioembolization with TheraSphere in HCC, (largest prospective RW dataset reported to date; n=989):
▪️ 68% tumors >5cm || 35% portal vein thrombosis
🎯 Higher absorbed tumor dose was associated with longer OS
💥 ≥400 Gy seemed particularly
👁 596❤ 13🔁 7
Colorectal (CRC)11 tweets · 5 trials
KRYSTAL-10adagrasib + cetuximab · 2L KRAS G12C mCRC
▼
ESMO GI 2026 is almost here.
After going through the scientific program, these are the 10 trials I’m watching most closely 👇
1️⃣ KRYSTAL-10
Can KRAS G12C-targeted therapy finally outperform chemotherapy in second-line mCRC?
2️⃣ STAR-221
Will TIGIT become the next immunotherapy
👁 24.1K❤ 98🔁 50
#ESMOGI26 | LBA1
KRYSTAL-10: Ph3 2L adagrasib + cetuximab vs SOC for KRAS G12C mCRC
No significant improvements in dual primary endpoints of PFS and OS.
@myESMO @OncoAlert
👁 1.1K❤ 15🔁 8
CAPRI-2 GOIMcetuximab continuum · molecularly-selected mCRC
▼
Should we continue cetuximab beyond first line in RAS/BRAF WT metastatic colorectal cancer? 🤔
The #ESMOGI26 CAPRI-2 GOIM trial suggests the answer may depend on ctDNA hyperselection. 🧬
Patients with:
✅ RAS/BRAF V600E WT
✅ MSS mCRC
✅ No acquired resistance alterations on https://t.co/jX5sLz5VPq
👁 9.8K❤ 38🔁 18
⚡ Rapid Oral Session at #ESMOGI26
🔸 PROACTIF / Y-90
🔸 AGEO-NEO-MSI
🔸 CAPRI-2 GOIM
🔸 Anti-EGFR retreatment
🧬 From real-world evidence to biomarker-driven strategies.
Promising data across GI cancers—now awaiting prospective confirmation and longer follow-up.
@OncoAlert
👁 1.5K❤ 28🔁 15
New data from CAPRI-2 GOIM trial (ESMO GI 2026 Rapid Oral)
Plasma ctDNA CGP can help identify “negative hyperselected” RAS/BRAF WT mCRC patients who derive meaningful benefit from continuing cetuximab by simply switching the chemo backbone (FOLFIRI → FOLFOX).
Key takeaway: 73%
👁 781❤ 6🔁 4
BREAKWATERencorafenib + cetux + mFOLFOX6 · BRAF V600E mCRC
▼
BREAKWATER Molecular Insights: Why Does EC + mFOLFOX6 Improve Survival?
Key findings
• ORR: 61% vs 40%
• PFS: HR 0.53
• OS: HR 0.49 (Median OS 30.3 vs 15.1 months)
What explains the benefit?
• Survival benefit was consistent across major molecular subgroups.
• Adding
👁 1.5K❤ 29🔁 16
Results from #BREAKWATER Cohort 3: @skopetz discusses updated findings which further support #encorafenib and #cetuximab plus #FOLFIRI as a first-line treatment option for patients with BRAF V600E-mutated #mCRC. Learn more: https://t.co/oJyvGUqTsB
👁 32❤ 0🔁 0
TORCH-iTNTIO-based total neoadj ± SCRT · LA rectal
▼
TORCH-iTNT: Does Adding SCRT to Neoadjuvant Chemoimmunotherapy Improve Outcomes in pMMR Rectal Cancer?
🔹 Complete response: 60.2% vs 37.3%
🔹 More Watch-and-Wait adoption: 27 vs 9 patients
🔹 No meaningful increase in Grade ≥3 toxicity
Bottom line: Adding SCRT to neoadjuvant
👁 1.0K❤ 13🔁 5
TORCH-iTNT would be a practise changing thing in pMMR if successful
👁 29❤ 0🔁 0
LAVA-CRLMMWA vs SBRT · oligomet CRLM
▼
Gastric / GEJ7 tweets · 2 trials
STAR-221D+Z+CT vs nivo+CT · HER2- GC/GEJC/EAC
▼
ESMO GI 2026 is almost here.
After going through the scientific program, these are the 10 trials I’m watching most closely 👇
1️⃣ KRYSTAL-10
Can KRAS G12C-targeted therapy finally outperform chemotherapy in second-line mCRC?
2️⃣ STAR-221
Will TIGIT become the next immunotherapy
👁 24.1K❤ 98🔁 50
#ESMOGI26 | 493O
STAR-221: Ph3 1L domvanalimab + zimberelimab + chemo vs nivolumab + chemo in HER2-neg GEA
Domvanalimab: anti-TIGIT, zimberelimab: anti-PD-1
As Taiho Pharma release last year, the addition of anti-TIGIT failed to demonstrate OS improvement.
@myESMO @OncoAlert
👁 984❤ 14🔁 7
STAR-221 negative at ESMO GI 2026.
Dual TIGIT + PD-1 blockade + chemo failed to improve OS over nivolumab + chemo in previously untreated HER2-negative advanced gastric, GEJ or esophageal adenocarcinoma.
No new safety signals.
Current standard of care stands.
Full summary
👁 577❤ 7🔁 2
HERIZON-GEA-01zanidatamab + CT ± TIS · 1L HER2+ mGEA
▼
1/ I keep coming back to this:
The only phase III upper GI trials showing survival benefit in PD-L1 negative patients are MATTERHORN and HERIZON-GEA…
Both used TAP/SP263 for the key PD-L1 subgroup analysis.
Coincidence?
👁 156❤ 2🔁 0
Biliary Tract / Upper GI:
🍊FGFR inhibition + IO + chemo (e.g., futibatinib + zimberelimab + GemCis in Phase 1, even #FGFR fusion-negative: promising ORR ~56%, mPFS ~9.7 months)
🍊 HER2-directed updates (e.g. #HERIZON-GEA-01 QoL/PFS2 analyses with #zanidatamab
👁 41❤ 0🔁 0
Biliary / Cholangiocarcinoma2 tweets · 1 trials
Futibatinib + Zimberelimab+ CT · 1L unresectable/mBTC
▼
Can FGFR inhibition improve first-line therapy in advanced biliary tract cancer?
Phase I data from ESMO GI 2026 showed promising activity with futibatinib + zimberelimab + GemCis in FGFR fusion-negative disease:
• ORR: 55.8%
• DCR: 97.7%
• mPFS: 9.7 months
• mOS: Not
👁 685❤ 7🔁 4
Biliary Tract / Upper GI:
🍊FGFR inhibition + IO + chemo (e.g., futibatinib + zimberelimab + GemCis in Phase 1, even #FGFR fusion-negative: promising ORR ~56%, mPFS ~9.7 months)
🍊 HER2-directed updates (e.g. #HERIZON-GEA-01 QoL/PFS2 analyses with #zanidatamab
👁 41❤ 0🔁 0
In the News
Media Coverage & Market Signals
Press & media coverage of ESMO GI 2026, kept separate from official company announcements and finance / investor chatter.
News & Press Coverage6 stories
MEDIA
Revolution's second RAS blocker doubles chemo response rate in pancreatic cancer
Zoldonrasib + mFOLFIRINOX hit an 82% ORR in 1L RAS-G12D mPDAC; Truist calls it the “path to leadership in PDAC.”
PRESSRevolution Medicines presents zoldonrasib combination data in RAS G12D mPDAC
Two orals: #340O (Wolpin) zoldonrasib+chemo 1L; #341O (Azad) zoldonrasib+daraxonrasib 2L+ — 2L ORR 50%, 3L+ 47%, DCR up to 97%.
PRESSHUTCHMED highlights pivotal Phase II fanregratinib data in FGFR2 ICC
Fanregratinib in FGFR2 fusion/rearrangement intrahepatic cholangiocarcinoma: DCR 83.9%, mPFS 6.9 mo, mOS 16.6 mo; NMPA priority review.
PRESSAgenus: 3-year survival from Phase 1b BOT+BAL in MSS mCRC
Botensilimab + balstilimab three-year survival in microsatellite-stable mCRC without active liver metastases (123-pt cohort).
MEDIATop Trials to Watch at ESMO GI 2026
Preview of CAPRI-2 GOIM, KRYSTAL-10, ATOMIC, EMERALD-1/-3, TRIPP-FFX, STAR-221, HERIZON-GEA-01, and dual RAS(ON) inhibition in G12D PDAC.
MEDIANew treatment modalities in GI cancers: broadening the horizon
ESMO editorial on molecular targeting, immunotherapy optimisation and novel drug classes reshaping GI oncology; RASolute 302 milestone.
Company Announcements9 accounts
COMPANY
At #ESMOGI26, we presented Phase 1/2 data for two combination regimens in RAS G12D metastatic pancreatic cancer. These results sup
COMPANYJoin Pfizer Oncology Medical team at #ESMOGI2026 in Munich, Germany next month (July 1-4) as we spotlight evolving insights and em
COMPANY📅 We’ll be attending #ESMOGI26!
We look forward to meeting with leading #oncology experts to share the latest research & insig
COMPANYUnderstanding treatment response in advanced/metastatic GEA remains a key focus.
At #ESMOGI26, a rapid oral presentation will fea
COMPANYPancreatic cancer remains one of the deadliest cancers in medicine.
At ASCO 2026, Daraxonrasib demonstrated meaningful progress,
COMPANYJoin us tomorrow at #ESMOGI2026 as Dr. Sara Lonardi presents ROSETTA CRC-203 TiP poster.
Join the poster session from 3:30 to
COMPANY#TeamBeOne is in Munich this week at #ESMOGI26 to share new data and exchange perspectives on the latest science in GI oncology. T
COMPANYWe've just released the following announcement: TRIPP-FFX Abstract Published on ESMO GI 2026 Website
Check out the full anno
COMPANYServier Invites to Explore Precision Medicine and Real-World Evidence in Cholangiocarcinoma at ESMO GI 2026
@Servier @ServierPhar
Finance / Investor Signals10 accounts
FINANCE
$ANL compelling preclinical
Data. These similar compounds ( to $RVMD daraxonrasib) tend to reproduce same xenografts findings in
FINANCE$RVMD Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer
FINANCE$RVMD Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer
FINANCE$RVMD
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metast
FINANCETRIPP-FFX abstract published ahead of 4 July ESMO GI presentation as @OncoSil_Medical met primary endpoints in LAPC trial $OSL.
FINANCEDaraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | New England Journal of Medicine
FINANCEThe fusion-negative angle is the story here. FGFR inhibitors (futibatinib, pemigatinib) are approved only in FGFR2 fusion-positive
FINANCERevolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
FINANCEThe more important point is the franchise read-through, not just the PT move.
If zoldonrasib + chemo can sustain strong 1L PDAC a
FINANCE$212 target up from $185 is a real signal.
Zoldonrasib 1L PDAC with no new toxicity
beyond chemo is the key detail.
Safety overh